Xuechun Liao1,#, Xiaoxiao Chen2,#, Shulan Wei1, Qiong Li1, Yanqin Zhao1, Yuying Xiao1, Qi Zhou1, Jianping Chen1,*, Jinlei He1,*
BIOCELL, Vol.50, No.5, 2026, DOI:10.32604/biocell.2026.077240
- 13 May 2026
Abstract Objective: Immune checkpoint blockade holds therapeutic potential in visceral leishmaniasis; its underlying mechanism remains unclear. This study aimed to investigate the therapeutic potential and underlying immune mechanisms of Programmed cell death protein 1 (PD-1) blockade in experimental visceral leishmaniasis. Methods: BALB/c mice infected with Leishmania donovani received anti-PD-1 antibody at 35–44 days post-infection. Parasite burden in target organs, serum antibodies, hepatopathology, and transcriptome of the liver were analyzed. T cell exhaustion, activation, apoptosis, and inflammation genes were quantified in target organs. Results: PD-1 blockade reduced splenic parasite load (reduction rate = 82.6%, ***p < 0.001), enhanced hepatic granulomatous… More >
Graphic Abstract